The association between upregulated Notch and FSH signaling and ovarian cancer is well documented. However, their signaling functions have been predominantly probed independently, and in the context of primary tumor tissues. The aim of this study was to investigate the interactive effects of FSH and Notch signaling on the formation and maintenance of disseminated metastatic ovarian cancer cells. We found that FSH upregulated Notch signaling in the ovarian cancer cells by increasing the expression of Notch receptors and ligands. The proliferation rate of the ovarian cancer cells was also increased in the presence of FSH. Further, high levels of FSH were detected in the ascites of patients with serous ovarian adenocarcinoma. The spheroids from the ascites of the patients, as well as, the spheroids from the ovarian cancer cell lines, expressed FSH subunit mRNAs and secreted the hormone into the medium. In contrast, primary ovarian tumor tissues and cell line monolayers expressed very low levels of FSH. Ovarian cancer cells cultured as spheroids exhibited higher expression of the FSH receptor (FSHR) and Notch downstream genes than countterpart monolayers. The Single chain Fragment variables (ScFvs) specific for the Negatively Regulatory Region (NRR) of Notch, and antibodies against the extracellular domain of FSHR, in combination, significantly inhibited spheroid formation and cell proliferation in vitro.
Introduction
Ovarian cancer is the leading cause of death among the gynecological malignancies [1] . One of the many risk factors recognized for the ovarian cancer is the excessive exposure of the normal ovarian surface epithelium to gonadotropins -Follicle stimulating hormone (FSH) and
Luteinizing hormone (LH) during menopause, ovulation or infertility therapy [2] [3] [4] . The gonadotropins are heterodimeric glycoproteins comprising a common  subunit associated noncovalently with the hormone-specific  subunit, secreted by the anterior pituitary and are essential for follicular development in the ovary [5] . In addition, FSH stimulates growth of the ovarian cancer cells [6, 7] while inhibiting apoptosis [8, 9] and high levels of FSH in the ascites of the ovarian cancer patients are inversely correlated to their survival [10] .
Notch signaling plays role in a wide spectrum of cell fate decisions. There are four Notch receptors (Notch1-4) and four ligands (Jagged1 and 2, Delta 1 and 4) known in mammals, and alterations in the Notch signaling pathway are associated with different cancers and are potential therapeutic targets [11, 12] . There is a direct link between aberrant Notch signaling and ovarian cancer progression [13] . Interestingly, FSH upregulates Notch1 receptor in ovarian cancer cells [14] .
With the progression of the ovarian cancer, the cancer cells detach from the primary tumor, either as single cells or cellular aggregates termed as spheroids, which either remain in the ascites and contribute to the recurrence of the disease or attach to the peritoneum for the development of secondary tumors [15] . The spheroids have been shown to be less susceptible to chemotherapy than the single cells and disruption of the spheroids resensitizes the ovarian tumor cells to chemotherapy with platinum-based drugs [16, 17] .
In this study, the link between FSH and Notch pathways has been investigated in more detail s using three different ovarian cancer cell lines. We demonstrate that FSH upregulates Notch signaling in these cell lines. Further, we demonstrate higher levels of FSH in the ascites of the ovarian cancer patients and trace the origin of this high FSH to the spheroids obtained from the patients.
Materials and Methods

Ovarian cancer cell lines
The ovarian cancer cell lines OVCAR-3, SKOV-3 and OVCAR-4 were authenticated by Short Tandem Repeat (STR) analysis. The OVCAR-3 cells were maintained in RPMI medium (Sigma) supplemented with 15% Fetal Bovine Serum (FBS) (GIBCO). The SKOV-3 cells were maintained in McCoys medium (Sigma) with 10% FBS. The OVCAR-4 cells were maintained in DMEM medium (Sigma) supplemented with 10% FBS. All media were supplemented with penicillin and streptomycin at the prescribed concentrations.
Hormone and Antibodies
The iodination grade-purified hormones and cAMP antiserum were obtained from the National Hormone and Peptide Program, NIDDK, National Institutes of Health. Polyclonal antibodies against FSH receptor (FSHR) extracellular domain (RF5) [18] and Notch3 receptor Negative regulatory region (NRR) were raised in the rabbits using the immunization protocol well established in the laboratory [19] . The Single chain variable fragments (ScFv) against the Notch3 NRR were isolated from the yeast display library using the standardized protocol [20] . The interesting ScFv clone (ScFv42) was expressed in E. coli. Bl21 and purified by His 6 tag affinity chromatography and used for further experiments.
FSH Receptor Binding assay
The binding of FSH to the receptors present on the ovarian cancer cell lines was analyzed by radio receptor assay. Radioiodination of FSH was carried out using the IODO-GEN method [21] . The specific binding of 125 I-FSH to the receptor preparations from the ovarian cancer cell lines was demonstrated as described earlier [22] .
In Vitro cAMP Measurement
Approximately 1 × 10 5 OVCAR-3 cells/well were plated in a 48-well plate and 24 hours later were incubated with fresh medium containing 1mM phosphodiesterase inhibitor 3-isobutyl-1methylxanthine (IBMX) for 30 minutes at 37 °C in a CO2 incubator (100μl) and then incubated with varying concentrations of FSH for 15 minutes at 37 °C (100μl). At the end of the incubation, the cells were lysed with the addition of 200μl of 0.2 N HCl, and the total cAMP produced was determined by cAMP Radio-immuno assay (RIA) as described earlier [18] .
Flow cytometry-based assays for the detection of FSH receptor and Notch receptors
The presence of FSH and Notch receptors on the ovarian cancer cell lines was demonstrated by flow cytometry-based assay. The ovarian cancer cells were detached from the tissue culture flasks using 0.5mM Ethylenediaminetetraacetic acid (EDTA) in Dulbecco's phosphate buffer saline (DPBS) and resuspended in a medium containing 10% FBS. Approximately 1X10 5 cells were incubated with the primary antibody (Notch3 NRR a/s or RF5 a/s for FSHR) at 1:500 dilution for 1 hour at 4 o C, followed by washing thrice with DPBS and resuspension in 100µl of the medium with 10% FBS and 1:1000 dilution of anti-rabbit secondary antibody-fluorophore conjugated (Invitrogen) for 45 minutes at 4 o C. At the end of the incubation, the cells were washed and resuspended in DPBS and analyzed using the Becton Dickinson Accuri C6 and the median fluorescence values were analyzed.
Luciferase reporter assay for the determining the Notch signaling activity
The Notch signaling in the ovarian cancer cell lines was determined as described earlier [23] .
Briefly, the ovarian cancer cell lines were seeded (5 X 10 4 cells/well) in 24 well plates and transfected with 790ng of 12XCSL (CBF1/Su(H)/Lag-1) reporter plasmid and 10ng of pGL3 basic or 800ng of pGL3 control along with 1ng of pRL-Tk using Lipofectamine 2000 (Invitrogen)
as per the manufacturer's instructions. The transfected cells were incubated with increasing concentrations of FSH in the presence or absence of RF5 a/s, Notch inhibitor DAPT (N-[N-(3,5difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester) (5µM) (Sigma) or ScFv42 (10µg/ml) and the Luciferase reporter activity was estimated using the Dual-luciferase assay kit (Promega) in TD200 Luminometer following the manufacturer's protocol.
Ovarian cancer cell line proliferation
The proliferation of the ovarian cancer cell lines in the presence of FSH or FSHR and Notch antagonists was determined using the BrdU (5-bromo-2'-deoxyuridine) incorporation assay.
Briefly, 5 × 10 3 cells were seeded per well in a 96-well plate. The cells were synchronized by incubating in medium without FBS overnight. Next day, the cells were treated with FSH or FSHR antibodies and Notch antagonists in the respective media supplemented with FBS. The cells were labeled with BrdU for 12 hours and its incorporation was determined as per the manufacturer's recommendation (Calbiochem).
Expression analysis by Real time PCR
The total RNA from the ovarian tumors or spheroids obtained from the patients' peritoneal tap, or from the ovarian cancer cell lines was isolated by Trizol based method. Briefly, the cells were washed with DPBS and lysed in Tri Reagent (Sigma). RNA was extracted according to the manufacturer's recommended protocol. cDNA was synthesized from 1 µg of total RNA using the cDNA preparation kit (Thermo Scientific) using the random primers. The transcript levels of the interested genes were analyzed using the Syber-Green (Thermo Scientific) in Eppendorf Realplex thermocycler. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or Ribosomal protein L35 (RPL35) were used as the internal controls. The ΔΔCt method was used to calculate the fold difference in transcript levels of different genes on various treatments. The sequences of the primers used in the analysis listed in the supplementary Table 1 .
Estimation of FSH in patients' ascites
The FSH levels in the ascites and sera of the patients as well as the hormone secreted by the ovarian cancer cell lines were determined by Radio-immuno assay (RIA) using the reagents supplied by the National Hormone Pituitary Agency (NHPP), USA.
Spheroid formation by different ovarian cancer cell lines
The cellular aggregates of the ovarian cancer cell lines were developed by culturing the cells under low attachment conditions. Briefly, the cells (~10 4 /well) were seeded in 96 well low attachment plates (NUNC sphera) and allowed to form aggregates for 24 to 96 hours. The aggregates were treated with RF5 a/s and/or ScFv42 at the different time points. At regular intervals, images of the aggregates were captured using the Zeiss microscope at 60X zoom.
Effect of different treatments on cellular aggregation or disaggregation was determined by analyzing the area of aggregates using a script developed in MATLAB R 15a (100 pixels in the image was equivalent to 150µm) fixing the ellipticity constant at 0.1.
Statistical analyses
The statistical analyses were performed using the Graphpad Prism 5.0 software. The p-value of < 0.05 was considered statistically significant. The experiments were repeated three times.
Results
FSH and Notch signaling in the ovarian cancer cell lines
Presence of the functional FSH receptor (FSHR) and Notch receptors in the ovarian cancer cell lines was demonstrated using different approaches. Presence of FSHR in these cells was demonstrated by determining specific binding of 125 I-FSH to the membranes obtained from OVCAR-3, SKOV-3 and OVCAR-4 cell lines. The membrane preparations were incubated with 125 I FSH in the presence of increasing concentrations of unlabeled FSH, binding was determined, and the binding data obtained were converted into Scatchard plots. As shown in Figure 1A , the dissociation constants of the OVCAR-3 and SKOV-3 were 1.7x10 -9 M and 1.9x10 -9 M respectively, while that of the OVCAR-4 was 2.8x10 -9 M. The Bmax for the receptor was highest in the OVCAR-3 cells ( Figure 1A ).
Presence of FSHR on the ovarian cancer cells was also confirmed by flow cytometry using the antiserum raised against FSHR (RF5 a/s) [18] . The cells were incubated with RF5 a/s and its binding was determined using anti-Rabbit IgG-FITC. As shown in the supplementary Figure 1A The functional nature of FSHR was further confirmed by determining the response of the OVCAR-3 cells to FSH in vitro. The cells (5X10 4 ) were incubated with increasing concentrations of FSH for 15 minutes at 37 o C and cAMP formed was determined by RIA. As shown in the Figure   1B , FSH produced a dose-dependent increase in cAMP. In the next experiment, the OVCAR-3 cells were incubated with FSH in presence and absence of the RF5 a/s, and cAMP produced was determined. As shown in Figure 1B , the response to the hormone was significantly inhibited in the presence of RF5 a/s indicating the antagonistic nature of the a/s [18] .
The presence of Notch receptors in the ovarian cancer cell lines was demonstrated by flow cytometry, using the a/s raised against the Negative regulatory region (NRR) of Notch3 receptor that has full cross reactivity with the Notch1 receptor (Supplementary Figure 1B) . As shown in the supplementary Figure 1C , all the three ovarian cancer cell lines exhibited binding of the NRR a/s, indicating the presence of Notch receptors on their cell surface. The Notch signaling in the OVCAR-3 cells, as determined by 12X CSL reporter, was stimulated by Dll4 (see below, Figure   2C ) and inhibited by DAPT ( Figure 1C ).
Effect of FSH on Notch signaling in the ovarian cancer cell lines
The possible effect of FSH on Notch signaling in the ovarian cancer cell lines was investigated by incubating the cell lines with increasing concentrations of FSH for 48 hours and determining Notch signaling in cells expressing a 12XCSL Luciferase reporter. As shown in the Figure 2A , in OVCAR-3 cells, there was an FSH dose-dependent increase in Luciferase activity indicating enhanced Notch signaling, which was further confirmed by the increased transcript levels of the Notch target genes Hes1, Hes5 and Heyl ( Figure 2B ). Similar results were obtained for SKOV-3 and OVCAR-4 ( Figure 3A and B). The stimulatory effect of FSH on Notch signaling was completely inhibited by the RF5 a/s, which by itself had no effect on Notch signaling. The hormone stimulated Notch signaling was also inhibited by DAPT ( Figure 2A ).
FSH also upregulated the expression of Notch1 and Notch3, as well as, the Notch ligands Dll1
and Dll4 in OVCAR-3 cells as determined by RT-PCR ( Figure 2B ). In addition, increase in the Notch receptors and Dll4 was also demonstrated by flow cytometry (supplementary Figure 2 ). In the case of OVCAR-4 cell line, the upregulation was observed predominantly of Notch3, as well as, the three ligands, Jag1, Dll1 and Dll4 ( Figure 3B ). Thus, increased Notch signaling in the ovarian cancer cell lines in response to FSH was a result of an increased expression of both Notch receptors and ligands.
Dll4 present on the surface of the stromal cells in the ovarian cancer microenvironment has been shown to be involved in the progression of the ovarian tumor [24] and as shown above, FSH upregulates Dll4 expression. Therefore, effect of exogenous Dll4 [23] together with FSH on the Notch signaling was determined. The OVCAR-3 cells were incubated with FSH (100mIU/ml) and the immobilized Dll4, individually and in combination, and the Notch signaling was determined. As shown in the Figure 
Effect of FSH and Notch ligand on the proliferation of ovarian cancer cell lines
The role of Notch signaling in the proliferation of ovarian cancer cell line is very well documented while as shown above, FSH upregulates Notch signaling in the ovarian cancer cell lines.
Therefore, the effect of FSH on the proliferation of OVCAR-3 cells was determined. The OVCAR-3 cells were incubated with increasing concentrations of the hormone for 48 hours and the BrdU incorporation was analyzed. As shown in Figure 4A , FSH stimulated OVCAR-3 cell proliferation in a dose-dependent manner.
Next, the effects of FSH and Notch ligand, individually and in combination, on the proliferation of OVCAR-3 cell line was examined. The cells were incubated with FSH and the immobilized Dll4 and the rate of proliferation was determined. As shown in Figure 4B , both ligands stimulated the cell proliferation in an additive manner. This increase in proliferation was inhibited by RF5 a/s, as well as, ScFv42. Further, the FSH-and Dll4-stimulated proliferation was inhibited by both RF5 a/s, as well as, the Notch3 NRR-specific ScFv even below the basal level.
FSH levels in Ovarian cancer patients' ascites
To understand the role of FSH and Notch signaling in the ovarian cancer progression, FSH levels in the ascites of the cancer patients were estimated. Ascites were obtained by peritoneal tap from 26 ovarian cancer patients while the serum samples were obtained from seven patients and FSH levels were determined by radioimmunoassay (RIA). FSH was detected in ascites of all the patients ranging from 15mIU/ml -208mIU/ml. The serum could be the possible source of FSH in the ascites. Average serum FSH level in post-menopausal Indian women (age 54 + 8) are 62 + 30 and premenopausal women are 25.8+10 mIU/ml [25, 26] . As shown in table 1 the ascitic FSH levels in twelve patients (# 2, 3, 6, 10, 11, 12, 13, 14, 17, 18, 23, 25) were more than 62 mIU/ml and the seven patients who had low FSH in their ascites, either did not have malignant cells detected in their ascites (# 1, 8, 9, 15) or were undergoing chemotherapy (#, 20, 21, 24) . Of the seven patients, whose serum samples were available for analysis, three patients (# 23, 25, 26) showed high FSH levels in both sera as well as ascitic fluids (> 100mIU/ml). However, in the case of remaining 4 patients, there was no correlation between serum and ascitic FSH levels.
To identify the source of the hormone in the ascites, ovarian tumors from the 6 ovarian cancer patients (Patient # 27-32) and multicellular spheroids from the ascitic fluid of 8 patients (Patient # 2, 3, 5, 10, 11, 13, 14 and 18) were obtained. The total RNA was isolated and subjected to RT-PCR analysis for FSHβ, FSH and FSHR transcripts. As shown in Table 1 , the primary ovarian patients tumor's samples exhibited high Ct values of FSH α and β suggesting very low hormone message in the primary tumors whereas the FSHR transcript levels were very high as indicated by the low Ct values in most of the samples (Patient # 27, 28, 29,30 and 31) . The other possibility of FSH being expressed by the metastatic tumor epithelium represented by spheroids in the ascitic fluids was next explored. Multicellular spheroids were isolated from the cell mass obtained from the ascites from patients and as shown in the Table 1 , the spheroids obtained from the patients 2, 3 ,10, 11, 13, 14 and 18 exhibited high levels of FSH message with lower cycle threshold (Ct) values compared to those obtained from the patient 5, an ovarian cancer patient with the recurrent disease. The FSHβ transcript levels were consistent with the ascitic hormone levels. Interestingly, there was not much difference in the expression of α subunit as depicted by the Ct values, whereas there was a significantly high expression of FSH receptor expression in the spheroids of the ovarian cancer patients (2, 3, 10, 11, 13, 14 and 18) compared to the patient 5 ( Table 1) .
Ovarian cancer cell lines spheroids
To simulate the conditions of in vivo spheroid formation, the ovarian cancer cell lines were cultured under the low attachment conditions that facilitated the cancer cells to aggregate and form compact spheroidal aggregates [27] . As shown in the Figure 5A Figure 5D and 5E, there was an increase in FSH transcripts under non-attachment conditions with corresponding increase in secreted FSH by OVCAR-3 and SKOV-3 cells, while there was neither any increase in the FSH transcripts nor in secreted FSH in the medium when the cells were grown as monolayer cells. The OVCAR-4 cells did not show any increase in FSH transcripts, as well as, the secreted hormone ( Figure   5F ).
Effect of FSH and Notch inhibitors on OVCAR-3 spheroids
It has been demonstrated that the formation of ovarian cancer cell line spheroids mimics the ovarian tumor metastatic condition and these spheroids exhibit chemo resistance as they increase in size [28] . Higher chemo resistance has also been correlated with increased Notch signaling [29, 30] . Therefore, the expression of Notch receptors, ligands and downstream genes was investigated under the conditions that facilitated spheroid formation. As shown in the Figure 6A In the next experiment, the effect of both these inhibitors on the preformed spheroids was investigated. The OVCAR-3 cells were grown under the low attachment conditions for 48 hours to form the aggregates and then either RF5 a/s or ScFv42 individually, or in combination were added. As shown in Figure 7B , there was a decrease in the mean aggregate size when both FSH and Notch signaling were inhibited.
Discussion
The etiology of ovarian cancer and carcinomatosis is not very well understood. Exposure to elevated levels of gonadotropin during cycles, post menopause or treatments for infertility and IVF have been implicated as the risk factors for the ovarian cancer [2] . FSH upregulated the genes involved in cellular proliferation and metabolism, while downregulating the apoptotic genes in the ovarian cancer cell lines [31, 32] . Interestingly, ovarian teratomas have been reported in FSHR "Gain-of-function" transgenic animals [33, 34] and the FSH receptor has also been considered as an effective immunotherapeutic target [35, 36] , clearly establishing the link between the hormone and ovarian cancer.
The link between FSH and Notch was indicated by increase in Notch1 expression by the hormone in SKOV-3 cells [14] . The TCGA database indicates an amplification of all Notch receptors, particularly Notch3, highlighting the involvement of Notch in the ovarian cancer. Both FSH and Notch have been shown to be involved in ovarian tumor angiogenesis, epithelial to mesenchymal transition, resistance to chemotherapy and cancer stem cell activity [2, 13] .
The present study is the first to demonstrate active FSH signaling in the ovarian cancer cell lines reported to be present on the stromal cells of the ovarian cancer [24] . When both Dll4 and FSH were present together, there was an additive increase in the Notch signaling. FSH increased proliferation of the ovarian cancer cell lines, which is in agreement with previous reports [6, 37] . This increase in proliferation was mediated by increased Notch signaling as it was inhibited by Notch3 NRR specific ScFv. The proliferation was brought even below the basal rates by the combination of Notch3 NRR ScFv and FSHR a/s. The progression of ovarian cancer frequently leads to accumulation of ascites in the peritoneal cavity of the patients which provides a complex mixture of soluble factors and cellular components creating a pro-inflammatory and tumor-promoting microenvironment for the cells [38] . FSH is probably one such factor and its levels in the ascites of twelve ovarian cancer patients out of 26 patients were significantly high. Earlier reports [39] also indicated the serum/tumor fluid FSH ratios to be low in the ovarian cancer patients suggesting that the origin of FSH in the ascites may not be the serum, which could be higher in the post-menopausal status of many of the patients [10] . The present study is however the first to posit that spheroids obtained from the ascites are the source of FSH. We observed that OVCAR-3 and SKOV-3 cells expressed FSHβ mRNA and secreted FSH into the medium only when cultured as spheroids, and not when grown as monolayers. However, the OVCAR-4 cells, when cultured as aggregates neither expressed FSH message nor secreted the hormone. Expression of the  subunit mRNA was observed in the cancer cell lines cultured both as monolayers and as spheroids, as well as, the spheroids obtained from the patients. In contrast, FSH expression is seen only when the cells are organized into the spheroidal geometries. In support of our cell line-based studies, the expression of FSH (and even FSH) was observed to be very low in cells from primary ovarian patient tumor samples. Despite low ligand expression, the FSHR expression was high. This suggests that the FSH secreted by ascitic spheroids might not just impact the morphogenesis of the latter, but also turn on FSH signaling in the FSHR expressing primary tumor driving its proliferation. This feedback loop however, is dependent upon the establishment of the metastatic niche, and might be perhaps one of the earliest examples of how the metastatic niche feeds back to alter the behavior of the primary tumor niche of a cancer. It is known that FSH expression is the rate limiting step in the secretion of the hormone from the pituitary [40] and once the  subunit expression is turned on, the heterodimeric hormone is secreted into the environment.
Turning 'on' of FSH expression in the spheroids is very intriguing and has not been reported earlier. Spheroids have been known to show altered epigenetic regulation with a general increase in histone acetylation [41] . However, the effect on FSH expression appears to be specific as neither the expression of LH is upregulated nor was there any secretion of LH under these conditions. Therefore, whether such a spheroid-specific expression and secretion of FSH is prognosticative of a metastatic, niche-specific secretome needs to be investigated further.
It is evident that FSH expressed by the ovarian cancer spheroids upregulates Notch signaling, which together with the stromal Dll4 leads to increased proliferation of the tumor cells. It was also interesting that the spheroidal cells also exhibited higher expression of FSHR (supplementary Figure 9 ) probably making them extremely sensitive to the increasing concentrations of the hormone. These data suggest that there is an autocrine regulation of FSH-FSHR signaling that plays an important role in the ovarian cancer progression.
The ovarian cancer cell spheroids are known to be associated strongly with the recurrence of the ovarian cancer, as they show resistance to chemo-and radio-therapies with larger spheroids being more resistant to the therapies [17] . Under these conditions, both FSH and Notch pathways are interesting immunotherapeutic targets. The Notch NRR ScFv42, individually, and in combination with FSHR a/s significantly inhibited the formation of bigger OVCAR-3 spheroids. The antibodies also decreased the average size of the pre-formed spheroids. These two antibodies inhibited ovarian cancer cell proliferation further, suggesting the potential therapeutic potential of these antibodies. Our observation that the FSHR antibody can perturb spheroidal morphogenesis individually but inhibit proliferation of monolayers only in an FSH-added condition suggests a morphology-specific higher activity of FSH signaling and its integration with Notch transduction. The mechanistic investigations of such signaling crosstalk will be explored in future endeavors.
In conclusion, in this study we demonstrate a clear link between FSH and Notch in the ovarian cancer progression and show that these are the potential targets for future therapeutic efforts. expression is plotted as transcripts per million. N is the number of samples [42] . Figure 4 .
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